课题基金 / 基金详情

COMBINATION THERAPY WITH ROSIGLITAZONE AND METFORMIN FOR TYPE 2 DIABETES

COMBINATION THERAPY WITH ROSIGLITAZONE AND METFORMIN FOR TYPE 2 DIABETES
罗格列酮和二甲双胍联合治疗 2 型糖尿病
批准号：
7374180
负责人：
Robert Roy Henry
金额：
$14.03万
依托单位：
UNIVERSITY OF CALIFORNIA, SAN DIEGO
依托单位国家：
美国
项目类别：
财政年份：
2006
资助国家：
美国
项目状态：
已结题
起止时间：
2006-04-01 至 2006-11-30
来源：
https://reporter.nih.gov/project-details/7374180
关键词：
combination therapydiabetes mellitusglucoseglucose metabolismmetforminnoninsulin dependent diabetes mellitusrosiglitazone

项目摘要

项目成果

Robert Roy Henry的其他基金

相似基金

相关文献

中文摘要
翻译
本子项目是利用由NIH/NCRR资助的中心赠款提供的资源的众多研究子项目之一。子项目和研究者（PI）可能已经从另一个NIH来源获得了主要资金，因此可以在其他CRISP条目中表示。列出的机构是中心的，不一定是研究者的机构。在2型糖尿病患者中，与最大剂量罗格列酮或二甲双胍相比，最初使用半最大剂量罗格列酮和二甲双胍联合治疗16周，通过葡萄糖处置率和糖化血红蛋白（HbA1c）测量对葡萄糖代谢的影响。检查对心血管危险因素的影响。
英文摘要
This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Examine the effect on glucose metabolism, as measured by glucose disposal rate and HbA1c, of initial use of half-maximal dose combination therapy with rosiglitazone and metformin for 16 weeks, compared with maximal doses of rosiglitazone or metformin, in subjects with type 2 diabetes mellitus. Examine the effect on cardiovascular risk factors.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Epicatechin and derivatives to preserve muscle structure function in diabetes
Epicatechin and derivatives to preserve muscle structure function in diabetes
Epicatechin and derivatives to preserve muscle structure function in diabetes
Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin
海外基金